Sverige - svenska - Läkemedelsverket (Medical Products Agency)

wirtschaftsgenossenschaft deutscher tierarzte (wdt) eg - bensylpenicillinprokainmonohydrat - intramammär suspension - 3 g - natriummetabisulfit hjälpämne; bensylpenicillinprokainmonohydrat 3 g aktiv substans - nöt

Europeiska unionen - svenska - EMA (European Medicines Agency)

co.don ag - sfäroider av humana autologa matrix-associerade kondrocyter - brosksjukdomar - andra droger för sjukdomar i muskel-skelettsystemet - reparation av symptomatiska ledbruskfel hos lårkondylen och knäets patella (international bruskjärnsförening (icrs) iii eller iv) med defektstorlekar upp till 10 cm2 hos vuxna.

Europeiska unionen - svenska - EMA (European Medicines Agency)

dany bienenwohl gmbh - oxalsyra dihydrat - ectoparasiticides för utvärtes bruk, inkl. insektsmedel - bin - för behandling av varroosis (varroa destructor) av honungsbin (apis mellifera) i kull-gratis kolonier.

Europeiska unionen - svenska - EMA (European Medicines Agency)

dany bienenwohl gmbh - oxalsyra dihydrat - ectoparaciticides, insecticides and repellents, ectoparasiticides for topical use, incl. insecticides - honey bees - för behandling av varroosis (varroa destructor) av honungsbin (apis mellifera) i kull-gratis kolonier.

Europeiska unionen - svenska - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - bimatoprost - glaucoma, open-angle; ocular hypertension - prostaglandin analogues, ophthalmologicals - reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).

Europeiska unionen - svenska - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunsuppressiva - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards).

Europeiska unionen - svenska - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - glecaprevir, pibrentasvir - hepatit c, kronisk - antivirala medel för systemiskt bruk, - maviret is indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults and children aged 3 years and older. maviret coated granules is indicated for the treatment of chronic hepatitis c virus (hcv) infection in children 3 years and older.

Europeiska unionen - svenska - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artrit, reumatoid - immunsuppressiva - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. ankylosing spondylitisrinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

bene-arzneimittel gmbh - pentosanpolysulfatnatrium - cystitis, interstitiell - urologiska - elmiron är indicerat för behandling av blåssmärtessyndrom som kännetecknas av antingen glomeruleringar eller hunner-lesioner hos vuxna med måttlig till svår smärta, brådskande och frekvens av miktur.

Europeiska unionen - svenska - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - leukemi, lymfocytisk, kronisk, b-cell - antineoplastiska medel - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.